With 29.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.25 whereas the lowest price it dropped to was $3.93. The 52-week range on CYCN shows that it touched its highest point at $9.47 and its lowest point at $1.27 during that stretch. It currently has a 1-year price target of $80.00. Beta for the stock currently stands at 1.74.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYCN was up-trending over the past week, with a rise of 96.31%, but this was up by 65.22% over a month. Three-month performance surged to 77.33% while six-month performance rose 56.70%. The stock gained 45.75% in the past year, while it has gained 65.22% so far this year.
Float and Shares Shorts:
At present, 2.53 million CYCN shares are outstanding with a float of 1.96 million shares on hand for trading. On 2024-10-31, short shares totaled 14439.0, which was 57.00000000000001 higher than short shares on 1727654400. In addition to Dr. Regina Graul Ph.D. as the firm’s President, Ms. Rhonda M. Chicko C.P.A. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.40410998 of CYCN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CYCN reported revenue of $194000.0 and operating income of -$1128000.0. The EBITDA in the recently reported quarter was -$1128000.0 and diluted EPS was -$0.29.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$30 being high and -$30 being low. For CYCN, this leads to a yearly average estimate of -$30. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
